NIH-Funding

Enhancing Central Neural Control of Mobility in Aging (U01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 10/25/2017 - 02:09
Funding Opportunity RFA-AG-18-019 from the NIH Guide for Grants and Contracts. The overall goal of this funding announcement is to solicit applications to investigate the central neural control of mobility in older adults without overt neurological diseases using innovative and cutting-edge methods that are emerging in neuroscience, geriatrics and mobility-related fields in aging research communities. This announcement also seeks information on the degree of plasticity in the aging brain and how this may be harnessed to maintain or improve mobility. Applicants are highly encouraged to adapt a multidisciplinary and collaborative approach that includes basic, clinical, and translational scientists. Mobility impairments are common in aging and are associated with a host of adverse events including disability and mortality. Identifying novel modifiable predictors of mobility decline will lead to mechanistic insights and the development of novel therapeutic interventions to enhance mobility as a person ages.
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 23:18

During the Continuing Resolution, the NIH operates at 90% of the FY17 budget levels, and the ICs do not know how much they will get in FY18, so yes, they are all extremely cautious until the future funding situation looks clear. Your PO needs to see the reviewer comments to determine how the internal discussion will go about your application (fellowships do not go to Council). After you get your summary statement, your PO will be able to advise whether to submit again for insurance (if that is possible for you to do) and also whether, if it looks unlikely that his/her IC will fund your application, whether he/she will release it to the PO in IC B for consideration for funding (though none of this would happen until after FY18 budget is passed – all very hypothetical). Hopefully your PO, after seeing the summary statement, will tell you to sit tight until the FY18 appropriation reaches IC A.

Categories: NIH-Funding

Reminder: FORMS-E Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2018

NIH Funding Announcements - Tue, 10/24/2017 - 12:33
Notice NOT-OD-18-009 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Request for Information (RFI) on Enhancing Utilization of the NIH Clinical Center

NIH Funding Announcements - Tue, 10/24/2017 - 12:19
Notice NOT-OD-18-007 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: Student123

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 09:46

Got my F32 impact score back and it is 28. It was reviewed at Institute A where they don’t publish the paylines. PO said to contact them when I have the summary statement back. The secondary institute that it was assigned to has published paylines and it is within their funding range. I’ve also been reading on here that all institutes are cautious at funding applications, until the FY18 is established. So I’m thinking I will not know for a while? Beginning of next year? Should I be cautiously optimistic or move on with my postdoc?

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 07:56

Here the guidance given to reviewers. https://grants.nih.gov/grants/peer/guidelines_general/Reviewer_Guidance_on_Rigor_and_Transparency.pdf

How well they follow it can vary……

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 07:52

It depends on what you work out with the other PI. It could move with him and you get a subcontract or you become the contact PI and it stays at your school (the easiest). The contact PI has to be at the institution that receives the grant. How you divide the money could be tricky but again that is up to you two to decide. What does your Multi-PI leadership plan say? If I was your Chair or Dean I might insist on keeping the grant since you are remaining.

Categories: NIH-Funding

Notice of Technical Assistance Webinar for Human Heredity and Health in Africa (H3Africa) RFAs: RFA-RM-17-020, RFA-RM-17-021

NIH Funding Announcements - Tue, 10/24/2017 - 04:03
Notice NOT-RM-18-001 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 22:30

I believe the “premise” is a bit more than the significance of the scientific concept and rationale for pursuing the work in that it includes the scientific basis of your objectives and approach. That is, the work may be broadly significant (eg, we need a vaccine for XYZ), but the scientific articles on which you base your hypothesis and approach may not be optimal (eg, papers cited are outdated, not appropriate for your proposed approach, wrong/different animal model used, relevant papers left out, etc.), so the premise of your specific project is weakened. I believe the goal is to hold PIs accountable for really understanding whether the literature they are citing is appropriate and genuinely supportive of/progressing toward their proposed work (vs just in the same scientific ballpark). And actually, Mike Lauer specifically addresses premise: https://nexus.od.nih.gov/all/2016/01/28/scientific-premise-in-nih-grant-applications/ (preliminary data also considered in assessing premise). However, I too would be curious as to whether/how SRGs have been addressing premise in their discussions.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 21:45

Your share of the award should stay the same. How much the other PI can take with him/her depends on how much of the work can be done at the new institution (ie, if the current institution or new institution is worse, as good, or better for conducting the work proposed). All this (including who is contact PI) will get worked out during the award negotiations as part of JIT, assuming the other PI has moved before JIT is requested and the award terms are prepared.

Categories: NIH-Funding

By: pjparker

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 19:48

Thank you…But what happens when the contact PI leaves and the multi-PI stays at the institution. How are the funds split up. And who is contact PI- the one that was named contact in the application or the one that stays with the institution.

Categories: NIH-Funding

By: DrSam

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 16:35

Over the last year, I am hearing that reviewers are also being asked to comment on the “premise” of the aims in a proposal. Not sure how different it is from what we had been writing previously under “rationale”, “justification”. Any pointers?

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 09:49

Technically the grant “belongs” to the institution. They have to agree to relinquish it. Professional courtesy usually lets a PI take grants with them when they leave. I suggest you do not do anything until you get the award. Then worry about transferring the grant to the new school. It is a messy/complex situation but not unusual. FYI, the Total amount of the grant won’t change. So if the indirect costs are higher at the new school the extra money will come out of direct costs. And Vice Versa.

Categories: NIH-Funding

By: Zdravka Medarova

WriteEdit-Grant Questions Blog - Fri, 10/20/2017 - 16:46

I have a question about Multi-PI grants. I am a Multi-PI together with another investigator from my institution. The other PI is the Contact PI. I just saw that we got a score of 19, 2%. The grant was reviewed this week. The other PI is leaving the institution. What happens to the budget. Can the other PI just take the entire grant with them. Is the grant awarded to the other institution since by the time Council meets, the other PI will have moved. Thank you

Categories: NIH-Funding

Building Research Capacity in Global Tobacco Product Regulation Program (U18)

NIH Funding Announcements - Fri, 10/20/2017 - 12:50
Funding Opportunity RFA-FD-18-003 from the NIH Guide for Grants and Contracts. The Food and Drug Administration announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDAs exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTPs) mission by utilizing the World Health Organizations (WHO) Member States expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.
Categories: NIH-Funding

Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)

NIH Funding Announcements - Fri, 10/20/2017 - 12:32
Funding Opportunity RFA-CA-17-044 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers. The DRSCs are designed to target the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Establish a network of multi-disciplinary research teams to study mechanisms of tumor resistance and sensitivity and develop innovative anti-cancer therapy strategies. The Coordinating Center to be established under this FOA will facilitate the activities of the DRSCs and help integrate the results of their studies.
Categories: NIH-Funding

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3)

NIH Funding Announcements - Fri, 10/20/2017 - 12:18
Funding Opportunity RFA-CA-17-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.
Categories: NIH-Funding

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24)

NIH Funding Announcements - Fri, 10/20/2017 - 12:18
Funding Opportunity RFA-CA-17-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.
Categories: NIH-Funding

Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R21-Clinical Trial Optional)

NIH Funding Announcements - Fri, 10/20/2017 - 11:58
Funding Opportunity PA-18-328 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support investigator-initiated R21 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.
Categories: NIH-Funding